S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Key facts

Sponsor

SWOG Cancer Research Network

Principal Investigator

Elisabeth Paietta, PhD, M.D

Our Lady of Mercy Medical Center

Intervention

cytogenetic analysis(genetic)

Enrollment

3341 enrolled

Eligibility

All sexes

Timeline

1991 – 2012

Study locations (30)

• Providence Cancer Center at Providence Hospital, Mobile, Alabama, United States
• Providence Cancer Center, Anchorage, Alaska, United States
• Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
• Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States
• Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States
• Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center, Burbank, California, United States
• Peninsula Medical Center, Burlingame, California, United States
• Tibotec Therapeutics - Division of Ortho Biotech Products, LP, Marysville, California, United States
• Sutter Health - Western Division Cancer Research Group, Novato, California, United States
• University of California Davis Cancer Center, Sacramento, California, United States
• California Pacific Medical Center - California Campus, San Francisco, California, United States
• Stanford Cancer Center, Stanford, California, United States
• Sutter Solano Medical Center, Vallejo, California, United States
• Poudre Valley Hospital, Fort Collins, Colorado, United States
• Front Range Cancer Specialists, Fort Collins, Colorado, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI) · Eastern Cooperative Oncology Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06326008
  Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
  Beijing GoBroad Hospital
• RECRUITINGPHASE2NCT06859424
  A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
  Center for International Blood and Marrow Transplant Research
• RECRUITINGPHASE2, PHASE3NCT06860269
  A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGNCT06895538
  Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
  Peking University First Hospital
• RECRUITINGNANCT06960993
  Mosaic Trial for Stem Cell Transplant Recipients
  Northwestern University
• RECRUITINGPHASE2NCT06816134
  Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE2NCT06608732
  Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
  Institute of Hematology & Blood Diseases Hospital, China
• ACTIVE NOT RECRUITINGNANCT05968963
  Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
  University of Miami

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement →